Carisoprodol Now a Controlled Substance in Louisiana
July 15, 2014 - The Louisiana Legislature has issued schedule changes for carisoprodol, placing it in schedule II of the Louisiana Uniform Controlled Substances Law, effective August 1, 2014. Carisoprodol is the generic form of the brand name medication Soma.
Combination products containing carisoprodol with codeine is already listed in Schedule III of the state and federal lists of controlled substances and remains in that schedule on both lists.
Effective August 1, the distribution, prescribing and dispensing of carisoprodol products (except the codeine combination product) shall adhere to the usual requirements applicable to Schedule II controlled substances.
Carisoprodol products are now classified as Schedule II Controlled Substances in the State of Louisiana and are subject to restrictions. As a result, prescriptions for carisoprodol products (with the exception of the combination product with codeine):
1) issued prior to August 1 expire 90 days after the date of issue
2) issued on or after August 1 may be issued in written or electronic form, are only valid for 90 days after the date it was written
3) refills are not allowed. Multiple partial fills are permitted provided the total quantity dispensed does not exceed the total quantity.
For members filling their prescription for carisoprodol in any strength, formulation or as a combination product containing any amount (except the codeine combination product) will now be required to obtain a new prescription even if there are refills remaining on their current prescription. If members have a prescription that was written prior to August 1, 2014 it can still be submitted to be filled only if it is no longer than 90 days old the day it is presented to a pharmacy.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.